Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 149


USA joins Canada, UK, Ireland and Austria in allowing people with insulin-treated diabetes to fly commercial aircraft.

Russell-Jones DL, Frier BM, Shaw KM.

Diabet Med. 2020 Feb 14. doi: 10.1111/dme.14273. [Epub ahead of print]


A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition.

Sanusi I, Sarnowski A, Russell-Jones D, Forni LG.

J Crit Care. 2019 Dec 10;57:19-22. doi: 10.1016/j.jcrc.2019.12.007. [Epub ahead of print]


A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes.

Bain S, Feher M, Fisher M, Hex N, Lee KCS, Mahon J, Russell-Jones D, Schou H, Wilmot EG, Baxter M.

Diabet Med. 2020 Feb;37(2):219-228. doi: 10.1111/dme.14180. Epub 2019 Nov 27. Review.


Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators.

N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.


Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.

Davies MJ, Russell-Jones D, Barber TM, Lavalle-González FJ, Galstyan GR, Zhu D, Baxter M, Dessapt-Baradez C, McCrimmon RJ.

Diabetes Obes Metab. 2019 Aug;21(8):1967-1972. doi: 10.1111/dom.13791. Epub 2019 Jun 18.


Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes.

Russell-Jones D, Dauchy A, Delgado E, Dimitriadis G, Frandsen HA, Popescu L, Schultes B, Strojek K, Bonnemaire M, Roborel de Climens A, Davies M.

Diabetes Obes Metab. 2019 Jul;21(7):1615-1624. doi: 10.1111/dom.13697. Epub 2019 Apr 30.


Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.

Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C.

Diabetes Ther. 2019 Feb;10(1):177-188. doi: 10.1007/s13300-018-0553-7. Epub 2018 Dec 13.


Patient power - Kidd Gloves.

Burge A, Green M, Russell-Jones D.

Clin Med (Lond). 2018 Oct;18(5):437. doi: 10.7861/clinmedicine.18-5-437. No abstract available.


Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.

Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, Mendis J, Russell-Jones D, Umpleby AM.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):359-368. doi: 10.1210/jc.2018-01176.


SGLT2 inhibitors in Type 1 diabetes: is this the future?

Herring R, Russell-Jones DL.

Diabet Med. 2018 Dec;35(12):1642-1643. doi: 10.1111/dme.13791. No abstract available.


Novel diabetes subgroups.

Feher MD, Munro N, Russell-Jones D, de Lusignan S, Khunti K.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):439. doi: 10.1016/S2213-8587(18)30126-8. No abstract available.


Lessons for modern insulin development.

Herring R, Russell-Jones DDL.

Diabet Med. 2018 Oct;35(10):1320-1328. doi: 10.1111/dme.13692. Epub 2018 Jun 15. Review.


Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort.

Bravis V, Kaur A, Walkey HC, Godsland IF, Misra S, Bingley PJ, Williams AJK, Dunger DB, Dayan CM, Peakman M, Oliver NS, Johnston DG; ADDRESS-2 Management Committee, Patient Advocate Group and Investigators.

BMJ Open. 2018 Apr 4;8(4):e020904. doi: 10.1136/bmjopen-2017-020904.


Fecal Enterobacteriales enrichment is associated with increased in vivo intestinal permeability in humans.

Pedersen C, Ijaz UZ, Gallagher E, Horton F, Ellis RJ, Jaiyeola E, Duparc T, Russell-Jones D, Hinton P, Cani PD, La Ragione RM, Robertson MD.

Physiol Rep. 2018 Apr;6(7):e13649. doi: 10.14814/phy2.13649.


Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957.

Bode BW, Bowering K, Russell-Jones D.

Diabetes Care. 2018 Mar;41(3):e29-e30. doi: 10.2337/dci17-0051. No abstract available.


Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.

Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T, Birk Østerskov A, Russell-Jones D.

Diabetes Obes Metab. 2018 May;20(5):1148-1155. doi: 10.1111/dom.13205. Epub 2018 Feb 4.


Identification of barriers to insulin therapy and approaches to overcoming them.

Russell-Jones D, Pouwer F, Khunti K.

Diabetes Obes Metab. 2018 Mar;20(3):488-496. doi: 10.1111/dom.13132. Epub 2017 Nov 22. Review.


Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.


A UK Civil Aviation Authority protocol to allow pilots with insulin-treated diabetes to fly commercial aircraft.

Mitchell SJ, Hine J, Vening J, Montague J, Evans S, Shaw KM, Frier BM, Heller SR, Russell-Jones DL.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):677-679. doi: 10.1016/S2213-8587(17)30264-4. No abstract available.


Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

Supplemental Content

Loading ...
Support Center